TAS-117 is a highly potent and selective, oral, allosteric pan-AKT inhibitor [20] with strong anti-proliferative activity against multiple tumor cell lines derived from human cancers, including breast, ovarian, gastric, endometrial, and myeloma (data on file, Taiho Pharmaceutical Co., Ltd.). The gene discussed is AKT1; the disease is plasma cell myeloma.